NBIX Share Price

Open 41.95 Change Price %
High 42.36 1 Day -0.05 -0.12
Low 40.98 1 Week -3.45 -7.64
Close 41.72 1 Month -1.36 -3.16
Volume 700629 1 Year 6.18 17.39
52 Week High 55.15
52 Week Low 33.56
NBIX Important Levels
Resistance 2 43.00
Resistance 1 42.47
Pivot 41.69
Support 1 40.97
Support 2 40.44
NASDAQ USA Most Active Stocks
FTR 2.11 -10.59%
FTR 2.11 -10.59%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
BGMD 0.06 20.00%
HAUP 0.06 20.00%
IDRA 2.49 19.14%
CLNT 3.08 16.23%
CGEI 0.36 16.13%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
QTWW 0.08 -50.00%
VALV 0.02 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Neurocrine Biosciences, Inc. (NASDAQ: NBIX)

NBIX Technical Analysis 3
As on 22nd Mar 2017 NBIX Share Price closed @ 41.72 and we RECOMMEND Sell for LONG-TERM with Stoploss of 46.17 & Sell for SHORT-TERM with Stoploss of 42.92 we also expect STOCK to react on Following IMPORTANT LEVELS.
NBIX Target for March
1st Target up-side 46.78
2nd Target up-side 48.61
3rd Target up-side 50.44
1st Target down-side 41.54
2nd Target down-side 39.71
3rd Target down-side 37.88
NBIX Other Details
Segment EQ
Market Capital 483944384.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.neurocrine.com
NBIX Address
NBIX
12780 El Camino Real
San Diego, CA 92130
United States
Phone: 858-617-7600
Fax: 858-617-7601
NBIX Latest News
Interactive Technical Analysis Chart Neurocrine Biosciences, Inc. ( NBIX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Neurocrine Biosciences, Inc.
NBIX Business Profile
Neurocrine Biosciences, Inc. (Neurocrine) discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders. The Company�s product candidates address some of the pharmaceutical markets including endometriosis, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine has 11 programs in various stages of research and development, including six programs in clinical development. It has entered into collaborations for six of its programs. Its lead clinical development program, elagolix, is a drug candidate for the treatment of endometriosis. The Company�s product portfolio include Elagolix, Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), CRF2 Peptide Agonist-urocortin 2, CRF1 Antagonist (561679), CRF1 Antagonist (586529), G Protein-Coupled Receptor 119 (GPR119), VMAT2, GnRH Antagonists, Antiepileptic Drugs, G Protein-Coupled Receptors and Indiplon.